A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF

The University of Alabama at Birmingham, Birmingham, Alabama, United States

University of Arizona, Tucson, Arizona, United States

Stanford University, Palo Alto, California, United States

UCSD, San Diego, California, United States

National Jewish Health, Denver, Colorado, United States

Emory University, Atlanta, Georgia, United States

Boston Children's Hospital, Boston, Massachusetts, United States

New York Medical College, Valhalla, New York, United States

The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

Oregon Health & Science University, Portland, Oregon, United States

University of Pittsburgh, Pittsburgh, Pennsylvania, United States

UT Southwestern Medical Center, Dallas, Texas, United States

University of Washington, Seattle, Washington, United States

Centre Hospitalier Régional Universitaire de Montpellier - Hôpital Arnaud de Villeneuve, Montpellier, France

Hôpital Necker Enfants Malades, Paris, France

UMC Utrecht, Utrecht, Netherlands

New Zealand Clinical Research (Part 1 Only), Auckland, New Zealand

University Hospitals Birmingham, Birmingham, United Kingdom

Royal Papworth Hospital, Cambridge, United Kingdom

Leeds Teaching Hospitals, Leeds, United Kingdom

King's College Hospital, London, United Kingdom

Nottingham University Hospitals, Nottingham, United Kingdom

University Hospital Southampton, Southampton, United Kingdom